What were the key takeaways from SIGA Technologies’s earnings call?

What is the revenue and EPS growth rate for SIGA Technologies year over year?

What factors drove the changes in SIGA Technologies's revenue and profit?

What does SIGA Technologies do and what are its main business segments?

What is the market's earnings forecast for SIGA Technologies next quarter?

What were the key takeaways from SIGA Technologies's earnings call?

What guidance did SIGA Technologies's management provide for the next earnings period?

What is SIGA Technologies's gross profit margin?

- **Financial Strength**: $155M cash reserve with no debt, supporting long-term growth and potential dividends.
- **International Momentum**: $13M Asia Pacific order underscores expanding global demand for TPOXX.
- **Government Partnership**: Ongoing U.S. engagement signals continued reliance on TPOXX for smallpox preparedness.
- **Pipeline Progress**: Pediatric formulation Phase I underway, with PEP indication submission targeted for 2027.
- **EMA Update**: CHMP expected to confirm smallpox treatment efficacy, excluding mpox indication.

**【CEO Summary Section】**
- SIGA emphasizes its role in global smallpox preparedness, with 2025 product revenues of $88 million, including $53M oral TPOXX and $26M IV TPOXX for the U.S. Strategic National Stockpile (SNS), plus $6M international sales.
- A $13M order from an Asia Pacific country highlights growing international demand, part of a multiyear contract allowing flexible order timing.
- The EMA's Tecovirimat-SIGA referral process is ongoing, with CHMP expected to issue a recommendation in March 2026, focusing on maintaining smallpox treatment indications while withdrawing mpox.
- Late-stage pipeline progress includes a Phase I study for a pediatric oral suspension, targeting FDA submission for post-exposure prophylaxis (PEP) in 12 months.

**【CFO Financial Commentary】**
- 2025 financials: $88M product revenues, $24M pretax operating income, $23M net income, and $0.32 diluted EPS.
- Strong cash position of $155M with no debt, supported by $27M U.S. government funding for development and $26M outstanding SNS order for 2026 delivery.
- International sales growth, with $6M from oral TPOXX and $7M in R&D revenue, reflecting diversified revenue streams.

**【Q&A Highlights】**
- **U.S. Government Engagement**: While no RFP timing is disclosed, SIGA remains engaged with HHS/ASPR, emphasizing TPOXX's strategic importance.
- **Capital Allocation**: CFO notes a disciplined approach to cash management, with potential special dividends and M&A opportunities to enhance shareholder value.
- **International Expansion**: Active discussions with multiple governments, with the $13M Asia Pacific order signaling broader global preparedness trends.
- **Pipeline Progress**: Pediatric formulation Phase I results expected in H2 2026, advancing PEP indication submission plans.


SIGA Technologies, Inc. (SIGA) Q4 2025 Earnings Call Transcript

- **Revenue Resilience**: $86 million in product revenue year-to-date, with $26 million in U.S. government orders pending delivery in 2026.
- **Pipeline Momentum**: Targeting FDA submission for TPOXX PEP in 2026 and pediatric IND submission by year-end.
- **EMA Review**: CHMP decision on Mpox efficacy expected soon; SIGA confident in TPOXX’s safety profile.
- **Financial Strength**: $172 million cash balance and no debt provide buffer against government shutdown delays.
- **International Expansion**: Anticipating multiple international sales in 2026 amid global biodefense spending growth.

**【CEO Summary Section】**
- SIGA reported $86 million in product revenue for the first nine months of 2025, including $53 million for oral TPOXX and $26 million for IV TPOXX under the U.S. government contract. International sales contributed $6 million.
- $26 million of IV TPOXX orders remain outstanding, expected to be delivered in 2026. Management anticipates multiple international sales in 2026.
- The European Medicines Agency (EMA) is reviewing TPOXX’s efficacy in treating Mpox, with a CHMP opinion or additional information request expected soon.
- Late-stage pipeline progress includes the TPOXX post-exposure prophylaxis (PEP) program for smallpox, targeting an FDA submission in 2026, and a pediatric formulation IND submission by year-end.
- SIGA maintains a strong financial position with $172 million in cash and no debt, having returned $230 million to shareholders since 2020.

**【CFO Financial Commentary】**
- Nine-month pre-tax operating income was $33 million, with a $10 million operating loss in Q3 due to lower product deliveries. Net income for the period was $29 million, or $0.40 per share.
- Q3 product revenue of $0.9 million related to IV tech transfer activities, with higher COGS driven by fixed storage and security costs.
- Research and development revenue totaled $5 million for the nine months, supporting government contracts and pipeline development.

**【Q&A Key Highlights】**
- **Government Shutdown Impact**: SIGA expects potential delays in CDC analysis for the PEP program but notes core government contracts remain unaffected. Strong cash reserves ($172 million) provide flexibility.
- **EMA Update**: Management is confident in TPOXX’s safety and efficacy, awaiting CHMP decision on Mpox efficacy review.
- **Financial Mitigation**: SIGA’s cash position exceeds four times annual operating expenses, enabling adaptation to government delays.
- **Pipeline Clarity**: PEP submission timeline may shift slightly due to CDC delays, but 2026 target remains unchanged.

SIGA Technologies, Inc. (SIGA) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 product revenues of $79 million, driven by U.S. government deliveries and $27 million in new development funding.
- **Pediatric Program Momentum**: $13 million BARDA funding to advance tecovirimat for children, with a Phase I/II trial targeting 2025.
- **CHMP Regulatory Challenge**: European referral for tecovirimat due to mpox data concerns, but company confident in smallpox efficacy.
- **Financial Strength**: $182 million cash balance, no debt, and net income of $35 million for the quarter.
- **Pipeline Expansion**: PEP indication submission planned for 2026 and evaluation of monoclonal antibodies for broad orthopoxvirus treatment.

**【CEO Summary Section】**
- Q2 2025 product revenues reached $79 million, comprising $53 million from oral TPOXX and $26 million from IV TPOXX deliveries to the U.S. Strategic National Stockpile.
- Received $27 million in incremental development funding under the BARDA 19C contract, including $14 million for manufacturing support and $13 million for the pediatric program.
- The U.S. government exercised an additional $26 million IV TPOXX order, expected to be fulfilled in 2026.
- Advanced the pediatric TPOXX program, targeting an IND submission in late 2025, with a Phase I/II trial evaluating a refined oral suspension formulation.
- Faced a CHMP referral for tecovirimat in Europe due to mpox trial data concerns, with plans to provide science-based responses.
- Progressed the PEP indication for smallpox, targeting FDA submission in 2026 following CDC analysis completion.
- Maintained international sales momentum, with $135 million in oral TPOXX sold to 30 countries since 2020.

**【CFO Financial Commentary】**
- Q2 2025 net income: $35 million (fully diluted EPS: $0.49), driven by $79 million in product sales and $2 million in R&D revenue.
- Pretax operating income: $46 million for the quarter, $43 million for the first half.
- Strong cash position: $182 million as of June 30, 2025, with no debt.
- Remaining outstanding U.S. government order: $26 million for 2026 IV TPOXX delivery.

**【Q&A Key Highlights】**
- **Pediatric Program Funding**: $13 million BARDA funding will support development up to regulatory filings, with a Phase I/II trial evaluating tecovirimat absorption in children.
- **CHMP Referral Impact**: While the referral may delay European regulatory progress, the company emphasizes tecovirimat's strong safety profile and smallpox efficacy data.
- **International Sales Strategy**: Focus on building relationships with 30+ countries, despite lumpy order timing, with a long-term view on global health security.
- **RFP Preparedness**: SIGA anticipates a potential U.S. government RFP, with a 6-month negotiation timeline based on historical precedent, though timing remains uncertain.
- **Monoclonal Antibodies Pipeline**: Evaluating development and manufacturing plans for preclinical monoclonal antibodies targeting orthopoxviruses, with potential standalone or combination therapies.

SIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call Transcript

- **Revenue Expansion**: $6M international sale and $70M U.S. government deliveries highlight strong Q1 execution.
- **Government Support**: $26M IV TPOXX order and $14M manufacturing funding underscore U.S. commitment to biodefense.
- **Pipeline Momentum**: PEP program on track for 2026 FDA submission; pediatric TPOXX IND planned for H2 2025.
- **Financial Strength**: $162M cash balance supports 4th consecutive dividend and strategic initiatives.
- **Strategic Positioning**: Expanding global reach, advancing regulatory approvals, and maintaining U.S. government partnerships drive long-term growth.

**【CEO Summary Section】**
- **International Sales Growth**: Q1 2025 product revenue of $6 million from a new international customer, marking expansion into new geographic regions beyond the $11 million Q4 2024 sale.
- **U.S. Government Contracts**: Delivered $53 million oral TPOXX and $9 million IV TPOXX to the Strategic National Stockpile (SNS) in April, with remaining IV deliveries expected by Q3. U.S. government exercised $26 million IV TPOXX option for 2026 delivery and added $14 million for IV manufacturing support over 2-3 years.
- **Pipeline Progress**: 
  - PEP program targeting FDA submission in H1 2026 after CDC sample analysis completion in Q4 2025.
  - Pediatric TPOXX IND submission planned for H2 2025 with clinical trials to follow.
- **Shareholder Value**: 4th consecutive special dividend of $0.60/share, reflecting strong balance sheet ($162M cash as of Q1) and confidence in future growth.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: 
  - Product Sales: $6M (international) + $62M (U.S. SNS deliveries in April)
  - R&D Revenue: $1M
- **Financial Performance**: 
  - Pretax operating loss: $2M
  - Net loss: $1M
  - Diluted loss per share: $0.01
- **Liquidity**: $162M cash with no debt, supporting dividend and strategic initiatives.

**【Q&A Highlights】**
- **RFP Timeline**: U.S. government actions (e.g., $26M IV option exercise) signal continued prioritization of TPOXX. SIGA expects to engage with ASPR on RFP when issued.
- **Tariff Impact**: No current impact on international sales or supply chain; U.S.-based manufacturing provides resilience.
- **Contract Modification**: $14M funding to enable IV tech transfer to third-party manufacturer, enhancing long-term supply chain reliability.
- **Share Buybacks**: Management maintains flexibility to deploy capital via dividends, buybacks, or growth investments, based on value maximization.


SIGA (SIGA)-8 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 2024 product sales of $133 million, up 2% YoY, with Q4 contributing $80 million. East Asia sale doubles prior region records.
- **International Expansion**: Japan approval for TPOXX and $11 million sale highlight global demand. Direct customer engagement post-Meridian handover.
- **Pipeline Momentum**: Vanderbilt monoclonal antibody license and PEP program targeting 2026 FDA submission.
- **Government Contracts**: $70 million in 2025 deliveries under existing contract; new RFP expected to reflect heightened smallpox threat awareness.
- **Financial Health**: $155 million cash balance, no debt. 2024 net income of $59 million, EPS of $0.82.

**【CEO Summary Section】**
- **2024 Financial Highlights**: Product sales reached $133 million, up 2% YoY, with $80 million generated in Q4. Oral TPOXX sales to the U.S. Strategic National Stockpile (SNS) and Department of Defense (DoD) drove 60% of revenue. An $11 million sale in East Asia marked a new international milestone.
- **International Expansion**: Assumed responsibility for TPOXX promotion outside the U.S. from Meridian Medical, enabling direct customer engagement. Japan's Pharmaceuticals and Medical Devices Agency approved TPOXX for orthopoxviruses, supported by comprehensive data from human and animal studies.
- **Pipeline Progress**: Exclusive license to Vanderbilt's monoclonal antibody portfolio for orthopoxviruses. TPOXX post-exposure prophylaxis (PEP) program targeting 2026 FDA submission.
- **Government Contracts**: $70 million in outstanding orders to be delivered in 2025 under the 19C contract. Engaging with the new ASPR to negotiate a follow-on contract, with potential for increased volumes reflecting heightened smallpox threat awareness.

**【CFO Financial Commentary】**
- **2024 Financial Performance**: GAAP net income of $59 million, fully diluted EPS of $0.82. Operating income of $70 million reflects disciplined cost management. Cash balance of $155 million at year-end, with no debt.
- **Revenue Mix**: 56% from oral TPOXX, 20% from IV TPOXX, 8% from DoD, and 17% from international markets. Research and development revenue of $5.4 million.
- **2025 Outlook**: $70 million in deliveries expected, with $49 million in inventory (including API) to support rapid response to future orders.

**【Q&A Key Takeaways】**
- **Order Delivery Timing**: $70 million in outstanding orders to be delivered in 2025, starting Q2. RFP process for a new contract is separate from current deliveries.
- **Dividend Policy**: Special dividend decision expected in Q2, with timing influenced by cash flow, market conditions, and capital allocation priorities.
- **International Sales**: $11 million Q4 sale in East Asia reflects growing demand for antiviral stockpiling. Japan Biotechno Pharma distribution agreement is more cost-efficient than prior partnerships.
- **MPOX Trials**: PALM 007 and STOMP trials highlighted potential benefits for early-treated or severe patients. SIGA will analyze subgroup data to inform future studies, though trial designs were not optimized for tecovirimat's mechanism of action.
- **Government Funding**: Despite NIH funding cuts, national security remains a bipartisan priority. SIGA's long-standing collaboration with U.S. agencies positions it to benefit from ongoing preparedness initiatives.

Actual									0	-0.04	0.98	-0.01	0.03	0.45	-0.01	-0.01	-0.04	-0.01	1.01	0.14	0.03	0.02	0.63	-0.01	0.49	-0.09	-0.08
Forecast
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Actual	--	--	--	--	--	--	--	--	8.65M	4.85M	115.40M	10.54M	16.67M	72.21M	11.40M	8.32M	5.88M	9.24M	116.50M	25.43M	21.81M	10.01M	81.40M	7.04M	81.12M	2.62M	3.80M
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	190.61M	--	--	--	--	--	--	--	--
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-38.88%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

SIGA

SIGA fundamentals

SIGA Q4 2025 Earnings

Earnings Call

You can ask Aime

SIGA

SIGA fundamentals

SIGA Q4 2025 Earnings

Earnings Call

SIGA Earnings Call Summary for Q4/20254:30 PM on Mar 10, 2026

SIGA Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

SIGA Earnings Call Summary for Q2/20254:30 PM on Aug 5, 2025

SIGA Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

SIGA Earnings Call Summary for Q4/20244:30 PM on Mar 11, 2025

You can ask Aime